Namir J. Hassan

South Parks Rd
Oxford, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 16 publications

Preclinical assessment of MAGE-A4-specific TCR-NK cells against solid tumors.

Preclinical assessment of MAGE-A4-specific TCR-NK cells against solid tumors.

Journal: Immunotherapy advances

Published: June 11, 2025

Development and characterisation of mgTHP-1, a novel in vitro model for neural macrophages with microglial characteristics.

Development and characterisation of mgTHP-1, a novel in vitro model for neural macrophages with microglial characteristics.

Journal: Neurological research

Published: November 07, 2023

Second Correction for Hassan et al., "CD6 Regulates T-Cell Responses through Activation-Dependent Recruitment of the Positive Regulator SLP-76".

Second Correction for Hassan et al., "CD6 Regulates T-Cell Responses through Activation-Dependent Recruitment of the Positive Regulator SLP-76".

Journal: Molecular and cellular biology

Published: March 21, 2019

Casting a wider net: Immunosurveillance by nonclassical MHC molecules.

Casting a wider net: Immunosurveillance by nonclassical MHC molecules.

Journal: PLoS pathogens

Published: February 22, 2019

An approved in vitro approach to preclinical safety and efficacy evaluation of engineered T cell receptor anti-CD3 bispecific (ImmTAC) molecules.

An approved in vitro approach to preclinical safety and efficacy evaluation of engineered T cell receptor anti-CD3 bispecific (ImmTAC) molecules.

Journal: PloS one

Published: May 17, 2018

Polyfunctional response by ImmTAC (IMCgp100) redirected CD8+ and CD4+ T cells.

Polyfunctional response by ImmTAC (IMCgp100) redirected CD8+ and CD4+ T cells.

Journal: Immunology

Published: January 18, 2017

Elimination of Latently HIV-infected Cells from Antiretroviral Therapy-suppressed Subjects by Engineered Immune-mobilizing T-cell Receptors.

Elimination of Latently HIV-infected Cells from Antiretroviral Therapy-suppressed Subjects by Engineered Immune-mobilizing T-cell Receptors.

Journal: Molecular therapy : the journal of the American Society of Gene Therapy

Published: November 03, 2015

Direct molecular mimicry enables off-target cardiovascular toxicity by an enhanced affinity TCR designed for cancer immunotherapy.

Direct molecular mimicry enables off-target cardiovascular toxicity by an enhanced affinity TCR designed for cancer immunotherapy.

Journal: Scientific reports

Published: September 30, 2015

ImmTACs for targeted cancer therapy: Why, what, how, and which.

ImmTACs for targeted cancer therapy: Why, what, how, and which.

Journal: Molecular immunology

Published: October 31, 2014

Case Report of a Fatal Serious Adverse Event Upon Administration of T Cells Transduced With a MART-1-specific T-cell Receptor.

Case Report of a Fatal Serious Adverse Event Upon Administration of T Cells Transduced With a MART-1-specific T-cell Receptor.

Journal: Molecular therapy : the journal of the American Society of Gene Therapy

Published: August 22, 2014

Examining the presentation of tumor-associated antigens on peptide-pulsed T2 cells.

Examining the presentation of tumor-associated antigens on peptide-pulsed T2 cells.

Journal: Oncoimmunology

Published: September 16, 2013

Identification of a Titin-derived HLA-A1-presented peptide as a cross-reactive target for engineered MAGE A3-directed T cells.

Identification of a Titin-derived HLA-A1-presented peptide as a cross-reactive target for engineered MAGE A3-directed T cells.

Journal: Science translational medicine

Published: August 09, 2013

Showing 1-12 of 16

Last Updated: 09/26/2026